Get the Stockscreener App
3.04
0.98%
-0.03
After Hours:
3.04
Puma Biotechnology Inc stock is traded at $3.04, with a volume of 386.05K.
It is down -0.98% in the last 24 hours and down -2.88% over the past month.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
See More
Previous Close:
$3.07
Open:
$3.11
24h Volume:
386.05K
Relative Volume:
0.66
Market Cap:
$149.23M
Revenue:
$226.63M
Net Income/Loss:
$15.38M
P/E Ratio:
9.50
EPS:
0.32
Net Cash Flow:
$35.61M
1W Performance:
+0.66%
1M Performance:
-2.88%
6M Performance:
-16.02%
1Y Performance:
-36.20%
1-Day Range:
$2.937
$3.154
1-Week Range:
$2.92
$3.17
52-Week Range:
$2.225
$7.73
Puma Biotechnology Inc Stock (PBYI) Company Profile
Name
Puma Biotechnology Inc
Sector
Industry
Phone
(424) 248-6500
Address
10880 WILSHIRE BLVD., LOS ANGELES, CA
Compare PBYI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
3.04 | 149.23M | 226.63M | 15.38M | 35.61M | 0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-28-21 | Upgrade | Citigroup | Neutral → Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Underperform |
| Oct-08-19 | Downgrade | Goldman | Neutral → Sell |
| May-10-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| May-10-19 | Downgrade | Citigroup | Buy → Neutral |
| Jan-17-19 | Initiated | Leerink Partners | Mkt Perform |
| Jan-03-19 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-19-18 | Upgrade | Goldman | Sell → Neutral |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-18 | Initiated | Goldman | Sell |
| May-11-18 | Reiterated | Stifel | Buy |
| Nov-10-17 | Reiterated | Citigroup | Buy |
| Nov-10-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-02-17 | Reiterated | Stifel | Buy |
| Sep-11-17 | Reiterated | Credit Suisse | Outperform |
| Jul-10-17 | Resumed | Leerink Partners | Outperform |
| Jun-06-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-25-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Mar-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
View All
Puma Biotechnology Inc Stock (PBYI) Latest News
Puma commences Phase II trial of alisertib for breast cancer treatment - MSN
What is Zacks Research's Forecast for PBYI FY2025 Earnings? - MarketBeat
Zacks Research Analysts Increase Earnings Estimates for PBYI - Defense World
Zacks Research Has Optimistic Outlook of PBYI Q4 Earnings - Defense World
Research Analysts Offer Predictions for PBYI Q4 Earnings - MarketBeat
Barclays PLC Increases Stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Is Now The Time To Put Puma Biotechnology (NASDAQ:PBYI) On Your Watchlist? - Yahoo Finance
Jane Street Group LLC Buys 16,374 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price - Simply Wall St
Zacks Research Has Negative Outlook of PBYI FY2024 Earnings - MarketBeat
Zacks Research Issues Pessimistic Estimate for PBYI Earnings - Defense World
FY2025 EPS Forecast for Puma Biotechnology Raised by Analyst - Defense World
FY2025 EPS Estimate for Puma Biotechnology Lifted by Analyst - MarketBeat
PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer - MSN
Geode Capital Management LLC Has $2.34 Million Holdings in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Barclays PLC Buys 46,370 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Best Momentum Stocks to Buy for January 6th - Yahoo Finance
Puma Biotechnology CEO Alan Auerbach sells $106,656 in stock By Investing.com - Investing.com Australia
Puma Biotechnology's SVP sells $27,208 in stock - Investing.com India
Puma Biotechnology chief commercial officer sells $29,742 in stock By Investing.com - Investing.com Australia
Puma Biotechnology chief commercial officer sells $29,742 in stock - Investing.com India
Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Jeffrey Jerome Ludwig Sells 9,437 Shares - MarketBeat
Alan H. Auerbach Sells 33,841 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) Stock - MarketBeat
Puma Biotechnology's SVP sells $27,208 in stock By Investing.com - Investing.com South Africa
Puma Biotechnology’s SVP sells $27,208 in stock By Investing.com - Investing.com Nigeria
Puma Biotechnology CFO sells shares worth $32,232 By Investing.com - Investing.com Australia
Puma Biotechnology CFO sells shares worth $32,232 - Investing.com
Puma Biotechnology CEO Alan Auerbach sells $106,656 in stock - Investing.com
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Franklin Resources Inc. Invests $41,000 in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
State Street Corp Has $1.53 Million Stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) - Defense World
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? - MSN
All You Need to Know About Puma Biotech (PBYI) Rating Upgrade to Strong Buy - Yahoo Finance
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why - MSN
Puma biotechnology sales earnings call - Ciudad Florida
Research Analysts Set Expectations for PBYI FY2025 Earnings - Defense World
What Every Investor Should Know: Understanding ROE Can Change Your Game! - Clinique Bio
Best Value Stocks to Buy for December 24th - MSN
Zacks Research Has Positive Outlook of PBYI FY2025 Earnings - MarketBeat
Should You Be Excited About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 33% Return On Equity? - Simply Wall St
Puma Biotech shares hold as analyst backs Buy rating on NCCN nod - Investing.com Canada
Puma Biotechnology (NASDAQ:PBYI) Given “Buy” Rating at HC Wainwright - Defense World
Best Momentum Stocks To Buy For December 24th - Barchart
Best Momentum Stocks to Buy for December 24th - Yahoo Finance
With 49% stake, Puma Biotechnology, Inc. (NASDAQ:PBYI) seems to have captured institutional investors' interest - Yahoo Finance
Puma Biotechnology's (PBYI) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Puma Biotechnology Inc Stock (PBYI) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):